Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,223 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.
Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L, Motoyama S, Ogata T, Kawakami H, Hsu CH, Adenis A, El Hajbi F, Di Bartolomeo M, Braghiroli MI, Holtved E, Ostoich SA, Kim HR, Ueno M, Mansoor W, Yang WC, Liu T, Bridgewater J, Makino T, Xynos I, Liu X, Lei M, Kondo K, Patel A, Gricar J, Chau I, Kitagawa Y; CheckMate 648 Trial Investigators. Doki Y, et al. Among authors: kim hr. N Engl J Med. 2022 Feb 3;386(5):449-462. doi: 10.1056/NEJMoa2111380. N Engl J Med. 2022. PMID: 35108470 Clinical Trial.
The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma.
Kim HS, Kim HR, Kim GM, Kim HS, Koh YW, Kim SH, Choi EC, Hong YK, Sung JH, Kim SM, Kim JH, Cho BC. Kim HS, et al. Among authors: kim sh, kim gm, kim hr, kim sm, kim jh. Cancer Chemother Pharmacol. 2012 Oct;70(4):539-46. doi: 10.1007/s00280-012-1933-8. Epub 2012 Aug 7. Cancer Chemother Pharmacol. 2012. PMID: 22868340
A prospective phase II trial of S-1 and cisplatin-based chemoradiotherapy for locoregionally advanced esophageal cancer.
Chang H, Shin SK, Cho BC, Lee CG, Kim CB, Kim DJ, Lee JG, Hur J, Lee CY, Bae MK, Kim HR, Lee SK, Park JC, Lee H, Kim HI, Chung H, Cha J, Lee YC, Kim JH. Chang H, et al. Among authors: kim cb, kim hi, kim dj, kim hr, kim jh. Cancer Chemother Pharmacol. 2014 Apr;73(4):665-71. doi: 10.1007/s00280-013-2371-y. Epub 2014 Feb 22. Cancer Chemother Pharmacol. 2014. PMID: 24562525 Clinical Trial.
Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.
Kim HS, Kwon HJ, Jung I, Yun MR, Ahn MJ, Kang BW, Sun JM, Kim SB, Yoon DH, Park KU, Lee SH, Koh YW, Kim SH, Choi EC, Koo DH, Sohn JH, Kim B, Kwon NJ, Yun HJ, Lee MG, Lee JH, Kim TM, Kim HR, Kim JH, Paik S, Cho BC. Kim HS, et al. Among authors: kim sb, kim b, kim sh, kim tm, kim hr, kim jh. Clin Cancer Res. 2015 Feb 1;21(3):544-52. doi: 10.1158/1078-0432.CCR-14-1756. Epub 2014 Nov 25. Clin Cancer Res. 2015. PMID: 25424851 Clinical Trial.
Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine.
Lee CK, Jung M, Choi HJ, Kim HR, Kim HS, Roh MR, Ahn JB, Chung HC, Heo SJ, Rha SY, Shin SJ. Lee CK, et al. Among authors: kim hr, kim hs. Cancer Res Treat. 2015 Oct;47(4):781-9. doi: 10.4143/crt.2014.261. Epub 2015 Feb 16. Cancer Res Treat. 2015. PMID: 25687848 Free PMC article. Clinical Trial.
An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer.
Lim SM, Chung WY, Nam KH, Kang SW, Lim JY, Kim HG, Shin SH, Sun JM, Kim SG, Kim JH, Kang CW, Kim HR, Cho BC. Lim SM, et al. Among authors: kim hg, kim sg, kim hr, kim jh. Eur J Cancer. 2015 Aug;51(12):1588-95. doi: 10.1016/j.ejca.2015.05.020. Epub 2015 Jun 9. Eur J Cancer. 2015. PMID: 26070683 Clinical Trial.
Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma.
Kim HS, Kim SM, Kim H, Pyo KH, Sun JM, Ahn MJ, Park K, Keam B, Kwon NJ, Yun HJ, Kim HG, Chung IJ, Lee JS, Lee KH, Kim DJ, Lee CG, Hur J, Chung H, Park JC, Shin SK, Lee SK, Kim HR, Moon YW, Lee YC, Kim JH, Paik S, Cho BC. Kim HS, et al. Among authors: kim hg, kim h, kim dj, kim sm, kim hr, kim jh. Oncotarget. 2015 Dec 29;6(42):44971-84. doi: 10.18632/oncotarget.6056. Oncotarget. 2015. PMID: 26462025 Free PMC article. Clinical Trial.
Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck.
Huang KK, Jang KW, Kim S, Kim HS, Kim SM, Kwon HJ, Kim HR, Yun HJ, Ahn MJ, Park KU, Ramnarayanan K, McPherson JR, Zhang S, Rhee JK, Vettore AL, Das K, Ishimoto T, Kim JH, Koh YW, Kim SH, Choi EC, Teh BT, Rozen SG, Kim TM, Tan P, Cho BC. Huang KK, et al. Among authors: kim sh, kim s, kim tm, kim sm, kim hr, kim hs, kim jh. Sci Rep. 2016 Jan 21;6:19552. doi: 10.1038/srep19552. Sci Rep. 2016. PMID: 26790612 Free PMC article.
3,223 results